Ocugen, Inc.


On June 10, 2021, Ocugen announced that it would "no looger pursue an emergency use authorization" for its COVID-19 vaccine candidate, Covaxin, and would instead go through the process of obtaining full approval. The company said that the decision was "based on a recommendation from the U.S. Food and Drug Administration," which also "requested more information and data" for the approval. The news shocked the market, as the Company had previously indicated that it intended to apply for emergency use authorization. Shares of Ocugen were down over 15% in morning trading.

Lead Plaintiff deadline
class period
Case Documents
No documents available. Contact us if you need a case document.